Denver Animal Protection warns public, pet owners after bats test positive for rabies
The first bat of the year to test positive in Denver was found in the Sloan Lake Neighborhood on July 8. On July 17, a family in the Highlands Neighborhood reported a second positive bat.
Rabies can be transmitted through saliva, usually through a bite from an animal with the disease. Authorities said the disease affects the nervous system and is usually fatal if symptoms develop. They stressed the importance of keeping pets up to date on their rabies vaccinations. A low-cost vaccine clinic is available at the Denver Animal Shelter on Tuesdays and Thursdays from 10:30 a.m. to 12:30 p.m.
The Fort Collins Natural Areas Program said, "Like all mammals, bats can get rabies. However, only ½ of 1% of bats contract rabies. When they do, they are very sick and usually die. If you see a bat on the ground or during the daytime, it might be sick. Don't touch it, keep children and pets away." You can learn more about the types of bats in Colorado here.
The Denver Department of Public Health and Environment urged the public to be cautious and avoid contact with bats and other wild animals. They said that most people in Denver come into contact with bats when they find their way into a home, and advised residents not to sleep with open and unscreened windows and doors. If a bat manages to enter the house, close it off and call Denver Animal Protection to remove it.
If an animal bites you, DAP said to flush the wound and wash thoroughly with soap and water, then contact your doctor. Someone bitten by an animal positive for rabies may be started on post-exposure prophylaxis treatment to prevent the development of the disease. All animal bites and scratches should be reported to DAP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Cluster of Legionnaire's disease cases found in NYC has health officials on alert
The city health department has launched an investigation after a cluster of Legionnaire's disease cases were identified in Harlem over the weekend — with officials urging New Yorkers to take precautions. Five cases of the potentially fatal pneumonia-like illness were diagnosed in the Manhattan neighborhood in recent days, although no deaths have been reported, the department said. 'Any New Yorkers with flu-like symptoms should contact a health care provider as soon as possible,' deputy chief medical officer Dr. Toni Eyssallenne said in a statement. 'Legionnaire's disease can be effectively treated if diagnosed early,' Eyssallenne said. 'But New Yorkers at higher risk, like adults aged 50 and older, those who smoke or have chronic lung conditions should be especially mindful of their symptoms and seek care as soon as symptoms begin.' Although potentially lethal if not treated in time, Legionnaire's disease is not contagious and can be treated with antibiotics, the department said. The disease is typically transferred through water supplies contaminated with Legionella bacteria that can pop up in plumbing systems, and can find favorable conditions in cooling towers, whirlpool spas, hot tubs, humidifiers and condensers in large air conditioning systems, health officials said. Last month, officials in Sydney, Australia, reported a death from a Legionnaire's case there. In October, a dozen cruise ship passengers were diagnosed with the disease in two cases, including 10 who had to be hospitalized, while another outbreak was reported at two Las Vegas casinos in 2023. In 2022, at least two dozen people in the Highbridge section of the Bronx were diagnosed with Legionnaire's, with two dying and others hospitalized with the disease. , Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Legionnaires' disease outbreak in Harlem leaves at least one dead, 22 others sickened as health officials raise alarm
A New Yorker has died and at least 22 others have been sickened in the Legionnaires' disease outbreak in Harlem, city health officials said in an alarming update. The cluster of pneumonia-like illness, initially detected on July 25, has been identified in several zip codes across Harlem, the New York City Health Department said Wednesday. Details were not given on the person who died. Deputy chief medical officer Dr. Toni Eyssallenne urged any New Yorkers with 'flu-like symptoms' to contact their health care provider as soon as possible. 'Legionnaires' disease can be effectively treated if diagnosed early,' Eyssallenne said. 'But New Yorkers at higher risk, like adults aged 50 and older, those who smoke or have chronic lung conditions should be especially mindful of their symptoms and seek care as soon as symptoms begin.' Although potentially deadly if not treated in time, Legionnaires' disease is not contagious and can be treated with antibiotics, the department said. The disease is typically transferred through water supplies contaminated with Legionella bacteria that can appear in plumbing systems and find favorable conditions in cooling towers, whirlpool spas, hot tubs, humidifiers and condensers in large air conditioning systems. All operable cooling towers in the area under investigation have been sampled — and the Health Department has ordered building owners with positive results to remediate the issue within 24 hours, officials said. The areas where cases have been confirmed are in five Harlem zip codes: 10027, 10030, 10035, 10037 and 10039, along with the bordering communities, the Health Department said. Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts
BROOMFIELD, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ('Aclarion' or the 'Company') (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that scan volume has achieved significant year over year growth of 132% from 2Q24 to 2Q25 and has demonstrated two consecutive quarters of growth for the first time. Scan volume growth is a key catalyst for driving revenue and securing favorable payments from insurance companies. Given the steady cadence of new physician adoption, the activation of new commercial sites in the U.S., CLARITY study sites completing the onboarding process, and the approval from three of the top four private insurance payers in the UK to cover Nociscan, the Company believes it is on a steady trajectory to deliver consistent quarter over quarter scan volume growth through the remainder of 2025 and beyond. Aclarion is pursuing two core key catalysts to drive value. The first is scan volume growth in the UK where the obstacle of not having approval from insurers to pay for Nociscan has been removed. Over 5.2 million people in the UK now have access to Nociscan through their insurance provider. This market serves as a bellwether for all future markets where reimbursement precedes broad physician adoption. The Company is pursuing an aggressive strategy in this market to drive awareness and adoption, first through our partners at The London Clinic, and then throughout the London market. In an encouraging sign, early results in the UK are driving the majority of Nociscan volume increases the Company is currently reporting and management expects to see this accelerate. 'The first half of 2025 was marked by significant scan volume growth as we continue to gain commercial traction and build upon the clinical and economic evidence through real-world studies and the CLARITY trial,' states Brent Ness, CEO, Aclarion. 'Seeing the volume grow in London following the positive coverage example of Axa, Vitality and Aviva in the UK market with our customer, The London Clinic, validates our strategy and fuels our confidence that the payer community will move to encourage use of Nociscan leading to consistent revenue growth.' The second key catalyst the Company is focused on to drive value is the CLARITY trial, as results of this trial are expected to be a critical drive to securing widespread insurance coverage in the United States. The Company believes CLARITY represents the first ever prospective randomized trial to link a non-invasive AI (augmented intelligence) algorithm to better surgical outcomes for patients with low back pain. With chronic low back pain being part of the highest cost diagnosis in the U.S., and clinical results from surgical intervention showing an average success rate of only 54% across the literature, the importance of additional information for surgeons to better match their surgical plan to the pain their patient is experiencing is critical. Nociscan provides this information by objectively measuring the biomarkers in each disc that have been demonstrated to correlate with pain. CLARITY is designed to prove that when a surgeon uses Nociscan in conjunction with their current surgical planning process, they achieve successful surgical outcomes for chronic low back pain that far exceed the industry average of 54%. The Company has now engaged eight Phase I sites with four sites fully onboarded and activated: Texas Back Institute, University of Miami Health, Advocate Health, and Northwestern Medicine. The remaining 4 Phase I sites are expected to be activated by end of year. The Texas Back Institute enrolled the first patient in June and the Company is on track to fully enroll all 300 patients by Q4 2026. As the CLARITY trial progresses, the Company will be conducting an internal analysis of three month clinical outcomes to get a preliminary look at how impactful Nociscan is in driving better early clinical outcomes. Although the formal CLARITY protocol calls for evaluating outcomes at the standard one and two year follow up milestones, management believes three month outcomes will provide highly predictive information about the ultimate formal results of the trial. The Company expects to have visibility into a meaningful number of three month patients in the second quarter of 2026. This information is expected to be a significant milestone and key catalyst for the Company. Additional 2025 key milestones and highlights include: EVIDENCE and PUBLICATIONS. A core component of driving payment coverage for Nociscan is building clinical evidence and more specifically, getting this evidence published in peer-reviewed journals. In 2Q25, Clinicoeconomics and Outcomes Research published an independent cost-effectiveness analysis of Nociscan, led by a renowned healthcare economist from UCSF. The analysis concluded that Nociscan is more effective and less costly than provocative discography, illustrating that Nociscan saves $1,712 per patient and improves surgical success rates by 10%. In addition to the cost-effectiveness analysis, Aclarion continues to invest in the development of real-world evidence with customers in the UK and US. Finally, in 4Q24, Siemens Healthineers published a featured Nociscan Case Study on their global website, MAGNETOM WORLD. Siemens Healthineers is a global market share leader in medical imaging, in-vitro diagnostics, and advanced therapies. CUSTOMERS. In the absence of Category I coverage by private health insurance companies in the U.S., and Aclarion's focus on driving scan volume in the UK, the Company remains very selective with regards to adding new customers outside of the UK. Three strategic U.S. customers were added in the first half of 2025, including Scripps Health in San Diego and the Spine Institute of Louisiana, both of whom are prioritizing development of real-world evidence. Additionally Medical Imaging Center of Southern California expanded Nociscan access to a second location in Santa Monica. Aclarion will continue to add customer sites in markets with strategic relevance and customers committed to excellence in spine care. CONFERENCES. A key component to securing payment for Nociscan in the U.S. is demonstrating the support of surgeons and securing the backing of key spine societies. Participating in professional conferences is a leading strategy to establish relevance and credibility amongst surgeons and their societies. In 1H25, Aclarion participated in six important industry conferences where use of MR Spectroscopy was discussed as a distinct innovation in low back pain. Nociscan specifically was presented by leading spine surgeons at three different conferences: the 28th Annual Selby Spine Conference, the 2025 Spine Summit, and the 20th Annual State of Spine Surgery Think Tank. The Company will continue to participate in key industry conferences in 2H25 including Bridging the Gap, the International Society of Pain & Neuroscience (ISPN) conference in London, Sonntag Spine Symposium, the NASS 40th Annual Meeting, The Radiological Society of North America, and the Minimally Invasive Spine Society. INTELLECTUAL PROPERY. In February, Aclarion secured its 24th US patent to protect expanded applications of Magnetic Resonance Spectroscopy (MRS) data processing to identify pain and infection biomarkers throughout the body. Currently Aclarion holds 24 US-issued patents, 13 European issued patents, as well as several pending patent applications. The Company is in the process of auditing its intellectual property portfolio to evaluate spinning off additional companies in partnership with private investors to optimize the value of the patent portfolio for shareholders without increasing burn. FUNDING. At the end of 1Q25, Aclarion announced a funding update that included raising nearly $15M (net) cash on hand, as well as eliminating all debt, no preferred equity, and no warrants with strike prices near the current market. These funding activities helped to ensure that Aclarion is fully NASDAQ compliant and funded to execute on the strategic objectives highlighted in company communications and outlined in this update. The Company reaffirms it is adequately funded through Q3 2026 to prove out the key catalysts of demonstrating significant scan volume growth in the UK and securing early visibility into the success of CLARITY. Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain and has the potential to drive better surgical outcomes. For more information about CLARITY, please visit: CLARITY Trial To find a Nociscan center, view our site map here. For more information on Nociscan, please email: info@ About Aclarion, Inc. Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ('MRS'), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as 'anticipates,' 'believes' and 'expects' or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contacts: Kirin M. Smith PCG Advisory, Inc. ksmith@ Media Contacts: Jennie Kim SPRIG Consulting jennie@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
